Dan Leonard
Stock Analyst at UBS
(3.17)
# 1,147
Out of 4,735 analysts
275
Total ratings
55.33%
Success rate
8.74%
Average return
Main Sectors:
Stocks Rated by Dan Leonard
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVTR Avantor | Downgrades: Neutral | $29 → $25 | $21.77 | +14.84% | 7 | Jan 17, 2025 | |
| CRL Charles River Laboratories International | Downgrades: Neutral | $250 → $185 | $169.81 | +8.95% | 6 | Jan 17, 2025 | |
| BRKR Bruker | Assumes: Neutral | $102 → $66 | $60.07 | +9.87% | 10 | Dec 10, 2024 | |
| TXG 10x Genomics | Maintains: Neutral | $25 → $20 | $16.16 | +23.76% | 3 | Oct 30, 2024 | |
| DHR Danaher | Maintains: Buy | $309 → $305 | $244.11 | +24.94% | 16 | Oct 23, 2024 | |
| CYRX Cryoport | Maintains: Neutral | $7 → $9 | $8.16 | +10.29% | 2 | Oct 18, 2024 | |
| MEDP Medpace Holdings | Downgrades: Neutral | $420 → $350 | $347.52 | +0.71% | 1 | Sep 27, 2024 | |
| CERT Certara | Upgrades: Buy | $16 | $12.61 | +26.88% | 9 | Sep 27, 2024 | |
| GH Guardant Health | Maintains: Buy | $32 → $40 | $45.13 | -11.37% | 8 | Aug 21, 2024 | |
| IQV IQVIA Holdings | Maintains: Buy | $295 → $300 | $205.69 | +45.85% | 12 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $420 → $385 | $348.95 | +10.33% | 19 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $420 → $385 | $353.86 | +8.80% | 19 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $105 → $125 | $123.95 | +0.85% | 1 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $80 | $78.75 | +1.59% | 10 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $17.63 | +98.53% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $160 → $150 | $152.57 | -1.68% | 21 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $200 | $141.31 | +41.53% | 16 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $11 | $5.23 | +110.33% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $70 | $167.46 | -58.20% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $90 | $54.26 | +65.87% | 9 | Aug 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $620 | $573.06 | +8.19% | 13 | Jul 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $7 | $7.45 | -6.04% | 2 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $345 | $413.81 | -16.63% | 12 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $260 | $205.07 | +26.79% | 5 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $160 → $145 | $152.65 | -5.01% | 10 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $90 | $70.37 | +27.90% | 12 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $60 → $62 | $47.50 | +30.11% | 3 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $330 → $340 | $243.99 | +39.35% | 11 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $22.18 | +8.21% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,350 → $1,500 | $1,324.48 | +13.25% | 8 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $45 → $35 | $12.57 | +178.44% | 12 | Aug 14, 2019 |
Avantor
Jan 17, 2025
Downgrades: Neutral
Price Target: $29 → $25
Current: $21.77
Upside: +14.84%
Charles River Laboratories International
Jan 17, 2025
Downgrades: Neutral
Price Target: $250 → $185
Current: $169.81
Upside: +8.95%
Bruker
Dec 10, 2024
Assumes: Neutral
Price Target: $102 → $66
Current: $60.07
Upside: +9.87%
10x Genomics
Oct 30, 2024
Maintains: Neutral
Price Target: $25 → $20
Current: $16.16
Upside: +23.76%
Danaher
Oct 23, 2024
Maintains: Buy
Price Target: $309 → $305
Current: $244.11
Upside: +24.94%
Cryoport
Oct 18, 2024
Maintains: Neutral
Price Target: $7 → $9
Current: $8.16
Upside: +10.29%
Medpace Holdings
Sep 27, 2024
Downgrades: Neutral
Price Target: $420 → $350
Current: $347.52
Upside: +0.71%
Certara
Sep 27, 2024
Upgrades: Buy
Price Target: $16
Current: $12.61
Upside: +26.88%
Guardant Health
Aug 21, 2024
Maintains: Buy
Price Target: $32 → $40
Current: $45.13
Upside: -11.37%
IQVIA Holdings
Jul 23, 2024
Maintains: Buy
Price Target: $295 → $300
Current: $205.69
Upside: +45.85%
May 8, 2024
Maintains: Buy
Price Target: $420 → $385
Current: $348.95
Upside: +10.33%
May 8, 2024
Maintains: Buy
Price Target: $420 → $385
Current: $353.86
Upside: +8.80%
Jan 16, 2024
Downgrades: Neutral
Price Target: $105 → $125
Current: $123.95
Upside: +0.85%
Dec 7, 2023
Initiates: Buy
Price Target: $80
Current: $78.75
Upside: +1.59%
Dec 7, 2023
Initiates: Neutral
Price Target: $35
Current: $17.63
Upside: +98.53%
Aug 16, 2023
Maintains: Outperform
Price Target: $160 → $150
Current: $152.57
Upside: -1.68%
Aug 10, 2023
Maintains: Neutral
Price Target: $225 → $200
Current: $141.31
Upside: +41.53%
Aug 8, 2023
Maintains: Neutral
Price Target: $14 → $11
Current: $5.23
Upside: +110.33%
Aug 4, 2023
Reiterates: Outperform
Price Target: $70
Current: $167.46
Upside: -58.20%
Aug 2, 2023
Maintains: Neutral
Price Target: $75 → $90
Current: $54.26
Upside: +65.87%
Jul 13, 2023
Upgrades: Outperform
Price Target: $620
Current: $573.06
Upside: +8.19%
Feb 15, 2023
Reiterates: Underperform
Price Target: $7
Current: $7.45
Upside: -6.04%
Aug 25, 2022
Initiates: Neutral
Price Target: $345
Current: $413.81
Upside: -16.63%
Aug 25, 2022
Initiates: Neutral
Price Target: $260
Current: $205.07
Upside: +26.79%
Feb 4, 2022
Maintains: Equal-Weight
Price Target: $160 → $145
Current: $152.65
Upside: -5.01%
Feb 3, 2022
Maintains: Overweight
Price Target: $95 → $90
Current: $70.37
Upside: +27.90%
Dec 14, 2021
Maintains: Equal-Weight
Price Target: $60 → $62
Current: $47.50
Upside: +30.11%
Dec 14, 2021
Maintains: Overweight
Price Target: $330 → $340
Current: $243.99
Upside: +39.35%
Aug 10, 2021
Initiates: Overweight
Price Target: $24
Current: $22.18
Upside: +8.21%
Jul 30, 2021
Maintains: Equal-Weight
Price Target: $1,350 → $1,500
Current: $1,324.48
Upside: +13.25%
Aug 14, 2019
Maintains: Hold
Price Target: $45 → $35
Current: $12.57
Upside: +178.44%